Celecoxib approved as NSAID with some concessions on class warning.
Miller
J L
JL
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D004348:Drug Labeling; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy; D011720:Pyrazoles; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib